Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study

Andrew D. Leavitt, Barbara A. Konkle, Kimo C. Stine, Nathan Visweshwar, Thomas J. Harrington, Adam Giermasz, Steven Arkin, Annie Fang, Frank Plonski, Anne Yver, Florence Ganne, Delphine Agathon, Maria de los Angeles Resa, Li-Jung Tseng, Gregory Di Russo, Bettina M. Cockroft, Liching Cao, Jeremy Rupon

Blood (2024) 143 (9): 796–806.

https://doi.org/10.1182/blood.2022018971

Published: 2024

Includes: Supplemental data

Journal Articles

Four-Year Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia Α

Thomas J. Harrington, Adam Giermasz, Nathan Visweshwar, Andrew D. Leavitt, Barbara A. Konkle, Jeremy Rupon, Gregory Dirusso, Li-Jung Tseng, Maria de los Angeles Resa, Florence Ganne, Delphine Agathon, Frank Plonski, Didier Rouy, Bettina M. Cockroft, Annie F. Fang, Steven Arkin

Blood (2023) 142 (Supplement 1): 1054.

https://doi.org/10.1182/blood-2023-179422

Published: 2023

Journal Articles

Long-Term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption and Safety of Hemophilia B Gene Therapy: Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec in Adult Patients with Severe or Moderately Severe Hemophilia B

Blood (2023) 142 (Supplement 1): 1055.

https://doi.org/10.1182/blood-2023-187624

Published: 2023

Journal Articles

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia Α

Adam Giermasz, Nathan Visweshwar, Thomas J. Harrington, Andrew D Leavitt, Barbara Konkle, Jeremy Rupon, Gregory Di Russo, Li-Jung Tseng, Maria de los Angeles Resa, Florence Ganne, Delphine Agathon, Frank Plonski, Didier Rouy, Bettina M. Cockroft, Annie Fang, Steven Arkin

Blood (2022) 140 (Supplement 1): 7776–7777.

https://doi.org/10.1182/blood-2022-159421

Published: 2022

Journal Articles

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a

Nathan Visweshwar, Thomas J. Harrington, Andrew D Leavitt, Barbara A. Konkle, Adam Giermasz, Kimo Stine, Jeremy Rupon, Gregory Di Russo, Li-Jung Tseng, Maria de los Angeles Resa, Florence Ganne, Delphine Agathon, Frank Plonski, Didier Rouy, Bettina M. Cockroft, Annie Fang, Steven Arkin

Blood (2021) 138 (Supplement 1): 564.

https://doi.org/10.1182/blood-2021-148651

Published: 2021

Journal Articles

Platelet Transfusions Prior to Lumbar Punctures, What Is the Evidence?

Shonali Midha, Rahul Mhaskar, Juan Felipe Rico, Akriti G Jain, Aryanna Jordan, Mintallah Haider, Damian A. Laber, Nathan Visweshwar, Michael Jaglal

Blood (2021) 138 (Supplement 1): 1916.

https://doi.org/10.1182/blood-2021-151868

Published: 2021

Journal Articles

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Steven W. Pipe, MD, Michael Recht, MD PhD, Nigel S. Key, MD, Frank W.G. Leebeek, MD PhD, Giancarlo Castaman, MD, Susan U. Lattimore, R.N., Paul Van Der Valk, Kathelijne Peerlinck, MD PhD, Michiel Coppens, MD, Niamh O'Connell, MD PhD, John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Peter Kampmann, MD, Karina Meijer, MD PhD, Annette von Drygalski, MD Pharm D, Guy Young, MD, Cedric Hermans, MDMRCP,PhD, Jan Astermark, MD PhD, Robert Klamroth, MD PhD, Richard S. Lemons, MD, Nathan Visweshwar, MD, Shelley Crary, MD MS, Rashid Kazmi, MBBS, Emily Symington, Miguel A. Escobar, MD, Esteban Gomez, MD, Rebecca Kruse-Jarres, MD, Adam Kotowski, MD, Doris Quon, MD PhD, Michael Wang, MD, Allison P. Wheeler, MD, Eileen K Sawyer, PhD, Stephanie Verweij, BSc, Valerie Colletta, MSc, Naghmana Bajma, MD, Robert Gut, MD PhD, Wolfgang A. Miesbach, MD PhD

Blood (2020) 136 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2020-143560

Published: 2020

Journal Articles

Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults with Severe Hemophilia a

Andrew D. Leavitt, MD, Barbara A. Konkle, MD, Kimo Stine, MD, Nathan Visweshwar, MD, Thomas J. Harrington, MD, Adam Giermasz, MD PhD, Steven Arkin, MD, Annie Fang, MD PhD, Frank Plonski, RN, MA, Lynne Smith, MBA, Li-Jung Tseng, PhD MBA, Gregory Di Russo, MD, Bettina M Cockroft, MD, Jeremy Rupon, MD, Didier Rouy, MD PhD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-137648

Published: 2020

Journal Articles

Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A

Barbara A. Konkle, MD, Kimo Stine, MD, Nathan Visweshwar, MD, Thomas J. Harrington, MD, Andrew D. Leavitt, MD, Adam Giermasz, MD PhD, Steven Arkin, MD, Gregory Di Russo, MD, Ashley Snyder, PharmD, MPH, Adrian Woolfson, MD PhD, Didier Rouy, MD PhD

Blood (2019) 134 (Supplement_1): 2060.

https://doi.org/10.1182/blood-2019-122143

Published: 2019

Journal Articles

A Meta-Analysis on the Efficacy of Thrombopoietin (TPO) Agonists in Reducing the Need of Platelet Transfusion before Procedures in Chronic Liver Disease Patients

Michael Jaglal, MD, Damian A. Laber, MD, Ankita K. Patel, MD, Mintallah Haider, MD, Jennifer Eatrides, MD, Nathan Visweshwar, MD, Hesham Abowali, MD

Blood (2019) 134 (Supplement_1): 2108.

https://doi.org/10.1182/blood-2019-129521

Published: 2019

Journal Articles

Incidence, Risk, and Markers of Thrombosis in AML Patients - Single Institution Experience

Blood (2018) 132 (Supplement 1): 5880.

https://doi.org/10.1182/blood-2018-99-120332

Published: 2018

Journal Articles

Validation of the Khorana Score in Acute Myeloid Leukemia Patients: A Single Institution Experience

Sayeef Mirza, MD MPH, Seongseok Yun, MD PhD, Najla Al Ali, M.Sc, Maher Elharake, MD, Nathan Visweshwar, MD, Daniel Schwartz, Katherine Robinson, MD, Ethan Nowell, BS, Grace Engle, Ibraahim Badat, Thomas Brimer, MD, Amra Kuc, Ashton Sequeira, MD, Sabbir Mirza, Dhiraj Sikaria, Jesus Diaz Vera, Noah Hackney, Rami S. Komrokji, MD, Michael Jaglal, MD

Blood (2018) 132 (Supplement 1): 2278.

https://doi.org/10.1182/blood-2018-99-117545

Published: 2018

Journal Articles

Meta-Analysis of Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Patients with Active Malignancy

Rahul Mhaskar, MPH, Gautamkrishna Koipallil, Nelson Thomas, Nathan Visweshwar, MD, Damian A. Laber, MD, Ankita K. Patel, MD, Michael Jaglal, MD

Blood (2018) 132 (Supplement 1): 363.

https://doi.org/10.1182/blood-2018-99-120271

Published: 2018

Journal Articles

Validation of the Khorana Score in a Large Cohort of Cancer Patients with Venous Thromboembolism

Ateefa Chaudhury, MD, Asha Balakrishnan, MD, Christy Thai, PharmD, BCPS, Bjorn Holmstrom, MD, Sowmya Nanjappa, MD, Zhenjun Ma, PhD, Junmin Zhou, PhD, Ankita Patel, MD, Nathan Visweshwar, MD, Michael V. Jaglal, MD

Blood (2016) 128 (22): 879.

https://doi.org/10.1182/blood.V128.22.879.879

Published: 2016

NARROW

Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study

Four-Year Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia Α

Long-Term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption and Safety of Hemophilia B Gene Therapy: Results from the HOPE-B Trial 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec in Adult Patients with Severe or Moderately Severe Hemophilia B

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia Α

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a

Platelet Transfusions Prior to Lumbar Punctures, What Is the Evidence?

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults with Severe Hemophilia a

Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A

A Meta-Analysis on the Efficacy of Thrombopoietin (TPO) Agonists in Reducing the Need of Platelet Transfusion before Procedures in Chronic Liver Disease Patients

Incidence, Risk, and Markers of Thrombosis in AML Patients - Single Institution Experience

Validation of the Khorana Score in Acute Myeloid Leukemia Patients: A Single Institution Experience

Meta-Analysis of Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Patients with Active Malignancy

Validation of the Khorana Score in a Large Cohort of Cancer Patients with Venous Thromboembolism

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only